Antiproliferative effects of γ-tocotrienol are associated with lipid raft disruption in HER2-positive human breast cancer cells.

[1]  P. Sylvester,et al.  Oxazine derivatives of γ- and δ-tocotrienol display enhanced anticancer activity in vivo. , 2014, Anticancer research.

[2]  P. Sylvester,et al.  γ-Tocotrienol-induced autophagy in malignant mammary cancer cells , 2014, Experimental biology and medicine.

[3]  P. Sylvester,et al.  Combined γ‐tocotrienol and Met inhibitor treatment suppresses mammary cancer cell proliferation, epithelial‐to‐mesenchymal transition and migration , 2013, Cell proliferation.

[4]  P. Sylvester,et al.  Tocotrienols target PI3K/Akt signaling in anti-breast cancer therapy. , 2013, Anti-cancer agents in medicinal chemistry.

[5]  V. Joulin,et al.  Pivotal role of the lipid Raft SK3-Orai1 complex in human cancer cell migration and bone metastases. , 2013, Cancer research.

[6]  P. Sylvester,et al.  Nonlinear Absorption Kinetics of Self-Emulsifying Drug Delivery Systems (SEDDS) Containing Tocotrienols as Lipophilic Molecules: In Vivo and In Vitro Studies , 2013, The AAPS Journal.

[7]  P. Sylvester,et al.  γ‐Tocotrienol inhibits HGF‐dependent mitogenesis and Met activation in highly malignant mammary tumour cells , 2011, Cell proliferation.

[8]  J. Baselga,et al.  Treatment of HER2-overexpressing breast cancer. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  Joshua J. Steffan,et al.  The polyphenol epigallocatechin‐3‐gallate affects lipid rafts to block activation of the c‐Met receptor in prostate cancer cells , 2010, Molecular carcinogenesis.

[10]  P. Sylvester,et al.  The Value of Tocotrienols in the Prevention and Treatment of Cancer , 2010, Journal of the American College of Nutrition.

[11]  D. Colomer,et al.  In vitro and In vivo Selective Antitumor Activity of Edelfosine against Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia Involving Lipid Rafts , 2010, Clinical Cancer Research.

[12]  P. Sylvester,et al.  Enhanced antiproliferative and apoptotic response to combined treatment of γ-tocotrienol with erlotinib or gefitinib in mammary tumor cells , 2010, BMC Cancer.

[13]  P. Sylvester,et al.  Anti‐proliferative effects of γ‐tocotrienol on mammary tumour cells are associated with suppression of cell cycle progression , 2010, Cell proliferation.

[14]  P. Sylvester,et al.  Combined γ-Tocotrienol and Erlotinib/Gefitinib Treatment Suppresses Stat and Akt Signaling in Murine Mammary Tumor Cells , 2010 .

[15]  J. Baselga,et al.  Novel anticancer targets: revisiting ERBB2 and discovering ERBB3 , 2009, Nature Reviews Cancer.

[16]  L. Penn,et al.  Reflecting on 25 years with MYC , 2008, Nature Reviews Cancer.

[17]  M. Cher,et al.  CXCL12/CXCR4 Transactivates HER2 in Lipid Rafts of Prostate Cancer Cells and Promotes Growth of Metastatic Deposits in Bone , 2008, Molecular Cancer Research.

[18]  P. Sylvester,et al.  Synergistic Antiproliferative Effects of γ-Tocotrienol and Statin Treatment on Mammary Tumor Cells , 2007, Lipids.

[19]  Helgi I. Ingólfsson,et al.  The inhibitory effect of (-)-epigallocatechin gallate on activation of the epidermal growth factor receptor is associated with altered lipid order in HT29 colon cancer cells. , 2007, Cancer research.

[20]  Faustino Mollinedo,et al.  Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts. , 2007, Blood.

[21]  K. Shokat,et al.  Escape from HER family tyrosine kinase inhibitor therapy by the kinase inactive HER3 , 2007, Nature.

[22]  P. Sylvester,et al.  γ‐Tocotrienol inhibits ErbB3‐dependent PI3K/Akt mitogenic signalling in neoplastic mammary epithelial cells , 2006 .

[23]  A. Vaughan,et al.  ATP-binding Cassette Transporter A1 Expression Disrupts Raft Membrane Microdomains through Its ATPase-related Functions* , 2006, Journal of Biological Chemistry.

[24]  Funda Meric-Bernstam,et al.  Advances in Targeting Human Epidermal Growth Factor Receptor-2 Signaling for Cancer Therapy , 2006, Clinical Cancer Research.

[25]  Edward S. Kim,et al.  Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. , 2006, Cancer research.

[26]  G. Hortobagyi,et al.  Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer , 2006, Nature Clinical Practice Oncology.

[27]  B. Berra,et al.  Role of gangliosides in the association of ErbB2 with lipid rafts in mammary epithelial HC11 cells , 2006, The FEBS journal.

[28]  L. Pike.  Growth factor receptors, lipid rafts and caveolae: an evolving story. , 2005, Biochimica et biophysica acta.

[29]  P. Sylvester,et al.  γ-Tocotrienol Inhibits Neoplastic Mammary Epithelial Cell Proliferation by Decreasing Akt and Nuclear Factor κB Activity , 2005 .

[30]  S. Loibl,et al.  Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells. , 2004, Neoplasia.

[31]  L. Chamberlain.  Detergents as tools for the purification and classification of lipid rafts , 2004, FEBS letters.

[32]  Q. She,et al.  Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  F. Maurer,et al.  The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[34]  L. Pike.  Lipid rafts Published, JLR Papers in Press, February 1, 2003. DOI 10.1194/jlr.R200021-JLR200 , 2003, Journal of Lipid Research.

[35]  P. Sylvester,et al.  Role of Caspase-8 Activation in Mediating Vitamin E-Induced Apoptosis in Murine Mammary Cancer Cells , 2003, Nutrition and cancer.

[36]  Sándor Damjanovich,et al.  Lipid rafts and the local density of ErbB proteins influence the biological role of homo- and heteroassociations of ErbB2 , 2002, Journal of Cell Science.

[37]  M. Freeman,et al.  Cholesterol-rich lipid rafts mediate akt-regulated survival in prostate cancer cells. , 2002, Cancer research.

[38]  F. Mollinedo,et al.  The antitumor ether lipid ET-18-OCH(3) induces apoptosis through translocation and capping of Fas/CD95 into membrane rafts in human leukemic cells. , 2001, Blood.

[39]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[40]  P. Sylvester,et al.  Antiproliferative and Apoptotic Effects of Tocopherols and Tocotrienols on Preneoplastic and Neoplastic Mouse Mammary Epithelial Cells (44544) , 2000, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[41]  Monilola A. Olayioye,et al.  The ErbB signaling network: receptor heterodimerization in development and cancer , 2000, The EMBO journal.

[42]  D. Stolz,et al.  Cross-talk between Epidermal Growth Factor Receptor and c-Met Signal Pathways in Transformed Cells* , 2000, The Journal of Biological Chemistry.

[43]  Johannes Gerdes,et al.  The Ki‐67 protein: From the known and the unknown , 2000, Journal of cellular physiology.

[44]  P. Sylvester,et al.  Antiproliferative and apoptotic effects of tocopherols and tocotrienols on normal mouse mammary epithelial cells , 2000, Lipids.

[45]  M. Sliwkowski,et al.  Binding specificities and affinities of egf domains for ErbB receptors , 1999, FEBS letters.

[46]  Sushmita Mukherjee,et al.  Endocytic Sorting of Lipid Analogues Differing Solely in the Chemistry of Their Hydrophobic Tails , 1999, The Journal of cell biology.

[47]  G. Carpenter,et al.  Heregulin degradation in the absence of rapid receptor-mediated internalization. , 1997, Experimental cell research.

[48]  M. Phillips,et al.  Cyclodextrins as catalysts for the removal of cholesterol from macrophage foam cells. , 1997, The Journal of clinical investigation.

[49]  Y. Yarden,et al.  Neu Differentiation Factor/Neuregulin Isoforms Activate Distinct Receptor Combinations* , 1996, The Journal of Biological Chemistry.

[50]  W. J. Johnson,et al.  Cellular Cholesterol Efflux Mediated by Cyclodextrins , 1996, The Journal of Biological Chemistry.

[51]  N. Normanno,et al.  Epidermal growth factor-related peptides and their receptors in human malignancies. , 1995, Critical reviews in oncology/hematology.

[52]  P. Sylvester,et al.  Potential role of tocotrienols in the treatment and prevention of breast cancer , 2014, BioFactors.

[53]  Y. Surh,et al.  The antitumor ether lipid edelfosine (ET-18-O-CH3) induces apoptosis in H-ras transformed human breast epithelial cells: by blocking ERK1/2 and p38 mitogen-activated protein kinases as potential targets. , 2008, Asia Pacific journal of clinical nutrition.

[54]  L. Rajendran,et al.  Raft association and lipid droplet targeting of flotillins are independent of caveolin , 2007, Biological chemistry.

[55]  P. Sylvester.  Vitamin E and apoptosis. , 2007, Vitamins and hormones.

[56]  R. Brown,et al.  Sphingolipid organization in biomembranes: what physical studies of model membranes reveal. , 1998, Journal of cell science.